Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) infection

Overview

Remdesivir (RDV) is an experimental drug being developed by Gilead Sciences. In experiments it has shown activity against SARS-2-CoV and multiple other similar types of viruses.

Description

Participants will receive Remdesivir (RDV) intravenously for 10 days. Participants will also complete questionnaires, blood and urine tests, vital measurements, and physical exams. Researchers will review participant medical records and contact participants via phone on Days 15 and 28 to follow up.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    COVID-19
  • Age: Between 18 Years - 100 Years
  • Gender: All

Individuals at least 18 years of age diagnosed with COVID-19 and requiring invasive mechanical ventilation.

Updated on 20 Nov 2022. Study ID: 2004458049

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center